Difference between revisions of "Team:ETH Zurich/Description"

(test)
Line 71: Line 71:
 
         <h2> References: </h2>
 
         <h2> References: </h2>
 
         <ul>
 
         <ul>
−
             <li><a name="cit1" class></a>[1] Maciej Chichlowski and Laura P Hale. “Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad”. In: <i>American Journal of Physiology-Gastrointestinal and Liver Physiology</i> 295.6 (2008), G1139–G1149.
+
             <li><a name="kaplan2015global" class></a>[1] Maciej Chichlowski and Laura P Hale. “Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad”. In: <i>American Journal of Physiology-Gastrointestinal and Liver Physiology</i> 295.6 (2008), G1139–G1149.
−
            <li><a name="cit2" class></a>[2] Mike G Laukoetter, Porfirio Nava, and Asma Nusrat. “Role of the intestinal barrier in inflammatory bowel disease”. In: <i>World Journal of Gastroenterology</i> 14.3 (2008), p. 401.
+
         
−
            <li><a name="cit3" class></a>[3] Eric J Archer, Andra B Robinson, and Gürol M Süel. “Engineered E. coli that detect and respond to gut inflammation through nitric oxide sensing”. In: <i>ACS synthetic biology</i> 1.10 (2012), pp. 451–457.
+
−
            <li><a name="cit4" class></a>[4] Jessica Ann Thompson et al. “Manipulation of the quorum sensing signal AI-2 affects the antibiotictreated gut microbiota”. In: <i>Cell reports</i> 10.11 (2015), pp. 1861–1871.
+
−
            <li><a name="cit5" class></a>[5] Timothy D Minogue et al. “The autoregulatory role of EsaR, a quorum-sensing regulator in Pantoea stewartii ssp. stewartii: evidence for a repressor function”. In: <i>Molecular microbiology</i> 44.6 (2002), pp. 1625– 1635.
+
−
            <li><a name="cit6" class></a>[6] Cynthia H Collins, Jared R Leadbetter, and Frances H Arnold. “Dual selection enhances the signaling specificity of a variant of the quorum-sensing transcriptional activator LuxR”. In: <i>Nature biotechnology</i> 24.6 (2006), pp. 708–712.
+
−
            <li><a name="cit7" class></a>[7] Gilaad G Kaplan. “The global burden of IBD: from 2015 to 2025”. In: <i>Nature Reviews Gastroenterology & Hepatology</i> 12.12 (2015), pp. 720–727.
+
 
         </ul>
 
         </ul>
 
     </div>
 
     </div>

Revision as of 11:02, 31 August 2016

PAVLOV'S COLI

Wiki under construction

★ ALERT!

This page is used by the judges to evaluate your team for the improve a previous part or project gold medal criterion.

Delete this box in order to be evaluated for this medal. See more information at Instructions for Pages for awards.

Tell us about your project, describe what moves you and why this is something important for your team.

What should this page contain?
  • A clear and concise description of your project.
  • A detailed explanation of why your team chose to work on this particular project.
  • References and sources to document your research.
  • Use illustrations and other visual resources to explain your project.
Advice on writing your Project Description

We encourage you to put up a lot of information and content on your wiki, but we also encourage you to include summaries as much as possible. If you think of the sections in your project description as the sections in a publication, you should try to be consist, accurate and unambiguous in your achievements.

Judges like to read your wiki and know exactly what you have achieved. This is how you should think about these sections; from the point of view of the judge evaluating you at the end of the year.

References

iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you thought about your project and what works inspired you.

Inspiration

See how other teams have described and presented their projects:

TEST

Inflammatory bowel disease (IBD) describes the chronic inflammations of parts of the intestine and is a collective of several further specified illnesses. The most common conditions are ulcerative colitis and Crohn's disease. It is classified as an autoimmune disease for which no cure has been developed. Current treatments include immunosuppression, surgery, antibiotics and nutritional therapies. This disease is a severe burden for the patients as well as it causes increasing direct (treatment) and indirect (absenteeism from work) costs for society. Furthermore, the number of reported cases is increasing world-wide4.

References:

  • [1] Maciej Chichlowski and Laura P Hale. “Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad”. In: American Journal of Physiology-Gastrointestinal and Liver Physiology 295.6 (2008), G1139–G1149.

Thanks to the sponsors that supported our project: